Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual
treatment (everolimus) in treating patients with somatostatin receptor positive bronchial
neuroendocrine tumors that have spread to other places in the body (advanced). Radioactive
drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and may
reduce harm to normal cells. Lutetium Lu 177 dotatate may be more effective than everolimus
in shrinking or stabilizing advanced bronchial neuroendocrine tumors.